T he importance of drug names has already been evidenced worldwide. A survey on biologics was conducted by Fernandez-Lopez et al 1 to gather the opinions of a small number of pharmacists involved in the Academy of Managed Care Pharmacy (AMCP), the American Society of Health-System Pharmacists (ASHP), or the American Pharmacists Association (APhA). Seventy-seven responding pharmacists indicated that they were more familiar with biosimilars (51; 66.2%) than with interchangeables (39; 50.6%). Of 75 pharmacists, 56 (74.6%) reported being confident or very confident with substituting an originator with an interchangeable if the drugs shared the same nonproprietary name. However, only 28 (37.3%) pharmacists felt confident or very confident in substituting an interchangeable that had a unique suffix distinct from the originator.
In Europe, biosimilars are not given unique names. Similar to how small molecule generic drugs in the United States adopt the same international nonproprietary names (INNs) as their corresponding brand reference drugs, European biosimilars share the same INNs. 2 These INNs are designated globally by the World Health Organization (WHO) for all medications (including biosimilars), but different countries can choose whether to adopt the INN or establish a different name. 1 For example, Europe assigned the same INN for a biosimilar to epoetin alfa, whereas Australia introduced the same biosimilar as epoetin lambda. 1 In an effort to reduce confusion, WHO has since developed an initiative to add biologic qualifiers (ie, a 4-letter code) to keep track of the biological product's manufacturer and manufacturing site. 1 The US Food and Drug Administration (FDA) recently proposed a naming system for biological medications that is reminiscent of what the WHO has established. For biosimilars, the FDA proposed that a unique 4-letter suffix be added to the INN. For interchangeables, the FDA requested comments on the following options: (a) same name -allow the original manufacturing company to choose a unique 4-letter suffix at the time of approval, which would then be assigned to future interchangeables; or (b) different names -allow a new manufacturing company to choose and keep a unique 4-letter suffix distinct from the original reference drug (ie, originator). 3 Although the comment period closed on October 27, 2015, comments can still be submitted to the FDA, according to 21 CFR 10.115(g) (5) . The comment submission due date simply allows the FDA to gather comments prior to drafting a final version of the guidance for industry. 4 Until the FDA presents the final guidance on the biosimilar naming system, there are areas of concern for which health care providers can begin preparing.
CONCERN OF CONFUSION
With different names for biosimilars (and perhaps for interchangeables), it will be essential to know how to access and use the Purple Book. Published in September 2014, the Purple Book lists all biological medications with notations on which medications are considered originators, biosimilars, and interchangeables. For all intents and purposes, the Purple Book is the "biological Orange Book" and may be used in the same manner as the Orange Book to determine which biological medication is biosimilar to or therapeutically interchangeable with an originator. 3
CONCERN OF DIFFERENCE
Biosimilars are not exact replicas of the originator, so health care providers need to decide whether specific biosimilars will be considered preferred drugs of choice or whether therapeutic interchange protocols will be acceptable for biosimilars, especially if they have been approved as interchangeables. Discussions regarding whether switches should be discouraged for patients who have finally been stabilized on a particular biosimilar may be necessary, as there are no data and further research is required.
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CONCERN OF DATA
Pharmacy and Therapeutics (P&T) Committees generally use clinical trial data to support formulary and protocol decisions, so the lack of data will be a major obstacle. Even with the current governmentinitiated trial in Norway, this biosimilar study is only observing the effects of switching from Remicade to an infliximab biosimilar (regardless of indication). 5, 6 Health care providers will need to hold discussions about the appropriateness (or inappropriateness) of extrapolating the study's findings to all other biologic medications and their respective biosimilars.
CONCERN OF SAFETY
Due to the potential risk of increased immunogenicity as well as a possible risk for hypersensitivity associated with switching between biosimilars, 7 it will be important to consider requiring meticulous documentation of biologic therapy initiation, interchanges, and discontinuations. Given the high probability of discontinuity of information amongst the different health care fields, it will be important to ensure that a biosimilar switch occurring at a community pharmacy will translate into proper documentation at the prescriber's clinic, for example.
CONCERN OF ERROR
Implementing an electronic database that is designed to distinguish which drugs are originators, biosimilars, and interchangeables may help reduce the risk of medication errors. Despite proper use of legend symbols, unique database characteristics will need to be considered. For example, how long does the drug name field need to be if drugs are in alphabetical order and the biological INN is long, followed by a 4-letter suffix? Should the 4-letter suffix come before the INN and be alphabetized accordingly to avoid accidentally choosing the wrong biosimilar?
Pharmacists will likely play a major role in transitioning to an era with biosimilars and interchangeable drugs since pharmacists interface with providers and patients as well as health insurance companies. Keeping abreast of the developments in the field of biologics will soon become a necessary asset for all pharmacists.
